![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, October 22, 2018 12:46:00 PM
We also believe in mgt consisting of the developer of Kevetrin and Prurisol, Dr. Krishna Menon, who many of us believe may one day win a Nobel Prize for his work in pioneering drug development, Dr. Arthur Bertolino, our President and Chief Medical Officer and the man guiding our drugs through the FDA labyrinth of getting drugs approved by the government, and Leo Ehrlich, our CEO, money man, and chief deal maker guiding IPIX through the financial war zones needed to get a bio startup to commercialization.
Many on this board vilify these men daily, for reasons one can only assume are due to their own personal agendas. The main focus of attack is Leo Ehrlich and he most often gets described as being here only for a large salary and to rob the company blind. I wish he could take legal action against these defamers.
But as Leo stated in the 1 June 2016 company PR dealing with Kevetrin Data Base Lock, Leo Ehrlich continued: “Cellceutix certainly has diversified its pipeline over the years, but I joined this company with the intent of finding a new cancer drug after losing both my parents to the disease." Leo has a greater purpose than financial gain in seeing Kevetrin succeed, he has the same passion of all shareholders who want to see cancer brought to its knees and Kevetrin looks like it may play a very important role in achieving this in the ensuing years.
IMO the views on this board are so heavily slanted to the dark side that one has to make a concerted effort at doing their own DD to realize the inherent value of IPIX. IMO it may be the largest opportunity a small investor could find in the market today. If you reached this board, you owe it to yourself to research it thoroughly (start with the company website) and also research the entire team of scientific advisors that believe our drugs could change the landscape of medicine to whit Irritable Bowel Diseases, AutoImmune Diseases, Cancers of many types, Dermatology conditions, Antibiotic that works against superbugs with little chance of them developing a resistance to it, and much more.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM